Higher LSD1 in Non-Seminomatous Germ Cell Tumors and LSD1 Inhibition by NCL1 Suppresses Embryonal Carcinoma Growth.
- 1Department of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
- 2Department of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
- 3Department of Complex Molecular Chemistry, SANKEN, The University of Osaka, Ibaraki, Japan.
Abstract
Lysine-specific demethylase 1 (LSD1/KDM1A) is a potential therapeutic target in non-seminomatous testicular germ cell tumors (NSGCTs). We assessed LSD1 and Ki-67 immunostaining in 74 histologically distinct tumor components from 53 patients with testicular germ cell tumors and studied the selective LSD1 inhibitor NCL1 in embryonal carcinoma models. LSD1 positivity was higher in pooled non-seminomatous than seminomatous components (p = 0.0104). Following Bonferroni correction, teratoma and yolk sac tumor components showed higher LSD1 positivity than seminoma, whereas the embryonal carcinoma-seminoma comparison did not reach statistical significance (adjusted p = 0.08). LSD1 positivity correlated with Ki-67 positivity. In embryonal carcinoma cells, NCL1 increased H3K9me2 enrichment at SOX2 and OCT4 promoter regions, decreased pluripotency-associated proteins and survivin, and increased cleaved caspase-3 and apoptotic cell populations while reducing cell viability. NCL1 also reduced viability in cisplatin-adapted cells and further reduced viability when combined with cisplatin in parental cells. In vivo, treatment initiated before tumors became measurable suppressed subsequent xenograft outgrowth, whereas treatment of established xenografts did not significantly inhibit growth at the doses tested. Together, the histological findings and responses observed in embryonal carcinoma models support LSD1 as a potential therapeutic target for further investigation in NSGCT; NCL1 efficacy in other histological subtypes and against established tumors remains to be established.
Related
- Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK Pathway [Retraction].
- Gilteritinib Suppresses Hepatocellular Carcinoma Cells in Association with Reduced Calpain-1 Expression and Inhibition of STAT3/AKT Signaling
- Apigenin suppresses ovarian cancer cell growth by disrupting TGF-beta1-mediated cancer–stroma interaction via AKT inhibition
- VGLL4 Suppresses Malignant Phenotypes of Clear Cell Renal Cell Carcinoma Cells Through Modulation of Hippo/YAP and Wnt/β-Catenin Signaling Pathways
- MYC Suppresses Mitochondrial Function in Hepatocellular Carcinoma through NRF1-Driven Receptor-Mediated Mitophagy
BibTeX
@article{shimizu2026higher,
title = {{Higher LSD1 in Non-Seminomatous Germ Cell Tumors and LSD1 Inhibition by NCL1 Suppresses Embryonal Carcinoma Growth.}},
author = {Nobuhiko Shimizu and Toshiki Etani and Taku Naiki and Aya Naiki-Ito and Yosuke Sugiyama and Takashi Nagai and Akihiro Murakami and Hiroyuki Kato and Toshiharu Morikawa and Maria Aoki and Masakazu Gonda and Hiroko Suzuki and Yohei Tsubouchi and Daiki Ishikawa and Takayoshi Suzuki and Satoru Takahashi and Takahiro Yasui},
journal = {Cancer science},
year = {2026},
month = oct,
doi = {10.1111/cas.70569},
url = {https://europepmc.org/article/MED/42908320},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Higher LSD1 in Non-Seminomatous Germ Cell Tumors and LSD1 Inhibition by NCL1 Suppresses Embryonal Carcinoma Growth.
AU - Nobuhiko Shimizu
AU - Toshiki Etani
AU - Taku Naiki
AU - Aya Naiki-Ito
AU - Yosuke Sugiyama
AU - Takashi Nagai
AU - Akihiro Murakami
AU - Hiroyuki Kato
AU - Toshiharu Morikawa
AU - Maria Aoki
AU - Masakazu Gonda
AU - Hiroko Suzuki
AU - Yohei Tsubouchi
AU - Daiki Ishikawa
AU - Takayoshi Suzuki
AU - Satoru Takahashi
AU - Takahiro Yasui
PY - 2026
DA - 2026/10/21
JO - Cancer science
DO - 10.1111/cas.70569
UR - https://europepmc.org/article/MED/42908320
AB - Lysine-specific demethylase 1 (LSD1/KDM1A) is a potential therapeutic target in non-seminomatous testicular germ cell tumors (NSGCTs). We assessed LSD1 and Ki-67 immunostaining in 74 histologically distinct tumor components from 53 patients with testicular germ cell tumors and studied the selective LSD1 inhibitor NCL1 in embryonal carcinoma models. LSD1 positivity was higher in pooled non-seminomatous than seminomatous components (p = 0.0104). Following Bonferroni correction, teratoma and yolk sac tumor components showed higher LSD1 positivity than seminoma, whereas the embryonal carcinoma-seminoma comparison did not reach statistical significance (adjusted p = 0.08). LSD1 positivity correlated with Ki-67 positivity. In embryonal carcinoma cells, NCL1 increased H3K9me2 enrichment at SOX2 and OCT4 promoter regions, decreased pluripotency-associated proteins and survivin, and increased cleaved caspase-3 and apoptotic cell populations while reducing cell viability. NCL1 also reduced viability in cisplatin-adapted cells and further reduced viability when combined with cisplatin in parental cells. In vivo, treatment initiated before tumors became measurable suppressed subsequent xenograft outgrowth, whereas treatment of established xenografts did not significantly inhibit growth at the doses tested. Together, the histological findings and responses observed in embryonal carcinoma models support LSD1 as a potential therapeutic target for further investigation in NSGCT; NCL1 efficacy in other histological subtypes and against established tumors remains to be established.
SN - 1347-9032
SN - 1349-7006
ER -